JACC Heart Fail. 2023 Aug;11(8 Pt 2):1084-1102. doi: 10.1016/j.jchf.2023.07.020.
ABSTRACT
There is growing evidence that severe tricuspid regurgitation (TR) impacts clinical outcomes in a variety of cardiovascular disease states. The late presentation of patients with advanced TR highlights the underappreciation of the disease, as well as the pitfalls of current guideline-directed medical management. Given the high in-hospital mortality associated with isolated tricuspid valve surgery, transcatheter options continue to be explored with the hope of improved survival and reduced heart failure hospitalizations. In this review, we explore the physiology of TR, discuss the etiologic classes of TR, and explore the transcatheter options for treatment and who might benefit from device therapy.
PMID:37611990 | DOI:10.1016/j.jchf.2023.07.020